Dorzagliatin
- Generic Name
- Dorzagliatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClN4O5
- CAS Number
- 1191995-00-2
- Unique Ingredient Identifier
- X59W6980E8
- Background
Dorzagliatin is under investigation in clinical trial NCT03173391 (Long-term Efficacy and Safety of HMS5552 in T2DM).
- Associated Conditions
- -
- Associated Therapies
- -
Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
- Conditions
- Diabetes MellitusPrediabetes / Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Elaine Chow
- Target Recruit Count
- 30
- Registration Number
- NCT06671340
- Locations
- 🇭🇰
Phase 1 Clinical Trial Centre, Hong Kong, Hong Kong
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
- Conditions
- Diabetic Nephropathy Type 2
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Yan Bi
- Target Recruit Count
- 106
- Registration Number
- NCT06222476
- Locations
- 🇨🇳
Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 20
- Registration Number
- NCT05468229
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT05098470
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Rita Basu, Birmingham, Alabama, United States
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 18
- Registration Number
- NCT04531631
- Locations
- 🇭🇰
The Chinese University of Hong Kong, Hong Kong, Hong Kong
DDI Study Between Dorzagliatin and Rifampicin
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 15
- Registration Number
- NCT04080609
- Locations
- 🇨🇳
Central Hospital of Xuhui District, Shanghai, Shanghai, China
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04080596
- Locations
- 🇨🇳
The 2nd Hospital of Jilin University, Changchun, Jilin, China
Drug Interaction Study Between Dorzagliatin and Empagliflozin
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 16
- Registration Number
- NCT03790787
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Hackensack, New Jersey, United States
Drug Interaction Study Between Dorzagliatin and Sitagliptin
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 15
- Registration Number
- NCT03790839
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.